Nanosonics Limited · ASX:NAN
Nanosonics — Investor Presentation (October 2009)
17 slides from Nanosonics's investor presentation, Oct 13, 2009
Slide 1: Nanosonics Limited (NAN)
Nanosonics Limited (NAN) David Radford –CEO 13 October 2009
Slide 2: Key Investment Highlights
Key Investment Highlights 12 months of delivering on commitments TGA approval 14 European distribution partners appointed Successfully transitioned from R&D to commercial entity Production validated and commenced Successful completion of a controlled roll out and sales to ANZ and targeted
Slide 3: Our vision: Commercialising innovative solutions to global challenges
Our vision: Commercialising innovative solutions to global challenges “At Nanosonics our goal is to safeguard the health and wellbeing of individuals, communities and environments by commercialising a stream of breakthrough disinfection and sterilisation technologies” David Radford, CEO and Executiv
Slide 4: Financials
Financials Category Date Amount Register segmentation Total shares on issue @ 1 October 09 196 million Share price @ 1 October 09 A$ 0.48 Market capitalisation @ 1 October 09 A$ 94.1 million Trading volume @ 1 October 09 150,000 shares/day Founders Retail 40% 45% Cash on hand @ 30 June 09 A$ 13.8 mi
Slide 5: Scope of the healthcare challenge
Scope of the healthcare challenge Golden staph kills 20% of patients Sydney Morning Herald, Monday 5th October Staphylococcus aureus bacteraemias: time to act, The Medical Journal of Australia, October 2009 • Forty per cent of cases of Staphylococcus aureus bacteraemia are hospital-acquired, and mos
Slide 6: Setting a new standard
Setting a new standard The only point of care low temperature solution available globally
Slide 7: Trophon EPR Competitive advantage
Trophon EPR Competitive advantage The only point of care low temperature solution available globally • Customer benefits – New standard in high level disinfection • Sporicidal capability – Short operating time • Process time only 7 minutes – Outstanding materials compatibility – No operator and pati
Slide 8: Launch product – Trophon EPR
Launch product – Trophon EPR The Opportunity • Current disinfection practices are known to be unacceptable • Nosocomial infections are costing Australia $1B p.a. • Materials compatibility problems with current technologies • OH&S issues with current use of toxic chemicals Ultrasound market attractiv
Slide 9: Global market opportunity
Global market opportunity Annual procedures Country / Region Radiology O&G Other Total Total Commercial update intracavity intracavity targeted targeted available market market ANZ 0.5M 1M 0.2M 1.7M 5.8M Rolled-out Western Europe 7M 16M 3M 26M 70M Roll out underway Canada 0.4M 0.9M 0.2M 1.5M 3.6M Un
Slide 10: Trophon EPR Competitive advantage: Current practices
Trophon EPR Competitive advantage Current practices
Slide 11: Trophon EPR – Strong regulatory driven demand
Trophon EPR – Strong regulatory driven demand • US – The Centers for Disease Control (CDC) recommends the use of hydrogen peroxide for high-level disinfection of intracavity probes. • Australia - High level disinfection recommended in between patients supported by the Australian Government professio
Slide 12: Trophon EPR – Positive customer validation
Trophon EPR – Positive customer validation “The Trophon EPR will make the task of disinfecting ultrasound transducers significantly faster, safer and more convenient and it is easily integrated into current medical practices and procedures” Dr Michael Cooper, Head of Gynaecology at Royal Prince Alfr
Slide 13: Product commercialisation
Product commercialisation Distribution channels • Local distribution partners in 14 European countries now appointed with recognised expertise in their local ultrasound market • OEM participation in global markets • Attractive margins driving distributor focus Sales strategy • Initial 6 month contro
Slide 14: Expanding the product range
Expanding the product range Nanosonics’ novel platform technologies are transferable and highly scalable to other significant markets
Slide 15: Product Pipeline
Product Pipeline Leveraging current NanoNebulant platform technology into a leadership position in low technology disinfection 13 Patent families aiding technology transfer • Endoscope/TEE probe disinfector at advanced prototype stage • Market potential:> A$ 400M Current development projects • Bed d
Slide 16: Summary
Summary Strong commercial demand and acceptance for Trophon EPR Global infection control awareness and regulation driving growth opportunities Expected entry to US market in 2010 (pending FDA approval) Manufacturing capability validated Focus on strong commercial product pipeline and partn
Slide 17: ssssesees
+4 tt ssssesees TITTTItt xr as eessssses TITITITT at nanoasoniilCs